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Background: Factors associated with survival in pemphigus have not yet been thoroughly addressed. Therefore, in
the present study, risk factors for overall mortality in a large group of patients with pemphigus vulgaris and foliaceus
were investigated.
Methods: A retrospective hospital-based cohort study was carried out, between October 1998 and November 2012, in
the Department of Dermatology of the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania.
The investigated prognostic endpoint was the overall survival of the patients.
Results: A total of 130 patients were studied (108 with pemphigus vulgaris and 22 with pemphigus foliaceus).
In pemphigus vulgaris group, univariate analysis found a statistically significant association between the age of onset
≥ 65 years (p < 0.001), presence of coronary heart disease (p = 0.006), presence of cardiac arrhythmia (p = 0.004), level of
anti-desmoglein1 autoantibodies ≥ 100 U/mL (p = 0.047) at diagnosis and the survival of the patients. An age-adjusted
analysis showed significant results for coronary heart disease. Multivariate analysis identified the age of onset ≥ 65 years
and the presence of coronary heart disease at diagnosis as independent risk factors associated with overall mortality. In
patients with pemphigus foliaceus, age of onset ≥ 65 years (p = 0.021) was associated with poor survival.
Conclusions: In addition to common prognostic factors, including older age and cardiovascular comorbidities, level of
autoantibodies was found to be a disease-specific factor associated with overall mortality in pemphigus vulgaris. The
newly identified factors have major implications for the stratification of patients and should greatly facilitate further
epidemiological studies in pemphigus. In addition, they provide useful information for the design of personalized
therapeutic plans in the clinical setting.
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Pemphigus encompasses a group of autoimmune blister-
ing skin diseases, characterized by autoreactive T and
B lymphocytes, targeting antigens of the intercellular
junctions of keratinocytes [1]. Two major forms of
pemphigus, pemphigus vulgaris (PV; ORPHA704) and
pemphigus foliaceus (PF; ORPHA79481), show specific* Correspondence: cassian@mail.sitaru.eu
†Equal contributors
2Department of Dermatology, University Medical Center Freiburg,
Hauptstrasse 7, 79104 Freiburg, Germany
4Centre for Biological Signalling Studies (BIOSS), University of Freiburg,
Freiburg, Germany
Full list of author information is available at the end of the article
© 2015 Baican et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.clinical, histological and immunopathological findings
[2]. If not treated, pemphigus vulgaris is often a fatal
disease. Despite the fact that prognosis of the condition
has dramatically improved after the advent of glucocorti-
coids and immunosuppresive therapy, recent population-
based studies documented an increased risk of death in
patients with pemphigus [3,4].
While several studies have been undertaken to evaluate
the risk factors for disease course, relapses and remissions
in patients with pemphigus [5-8], few investigations evalu-
ated the risk factors for overall mortality in patients with
PV [9-12] and none for PF as a separate entity.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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suggesting that an older age of onset [3,10,11,13],
concomitant involvement of the skin and mucosal
surface at early disease presentation [9,14,15], delayed
initiation of corticosteroid treatment [9] and the
therapeutic combination of corticosteroids plus azathi-
oprine, vs corticosteroids alone [11] are possible risk
factors for overall mortality in patients with pemphigus.
Further putative risk factors, including comorbidities
and pathogenetically-relevant immunopathological fea-
tures have not yet been assessed sistematically. There-
fore, in a hospital-based retrospective approach, we
aimed to identify possible risk factors for overall mor-




This retrospective cohort study was performed in the
Department of Dermatology at the University of Medicine
and Pharmacy “Iuliu Hatieganu”, from Cluj-Napoca,
Romania. Patients diagnosed between October 1998
and November 2012 were included. The study was
approved by the local Ethic Committee and performed
in accordance with the Declaration of Helsinki.
Patients
The study group consisted of hospitalized or ambulatory
patients, which were included in clinical files and elec-
tronic data bases. Epidemiological, clinical and immuno-
logical data were collected from patients' medical records.
Death records data were obtained from the National
Population Register. Missing data from patients’ files were
obtained from the patients themselves by the use of tele-
phone interviews. An informed consent was signed by all
patients.
Inclusion criteria for patients with PV were: 1) presence
of skin bullae and/or erosions on mucous membranes, 2)
intraepidermal acantholysis on histopathological examin-
ation of skin and/or mucosa biopsies, 3) intraepidermal
IgG and/or C3 deposits by direct immunofluorescence
and presence of anti-desmoglein 3 +/− anti-desmoglein 1
autoantibodies, measured by ELISA method. Inclusion cri-
teria for patients with PF were: 1) presence of skin bullae,
2) lack of mucosal lesions, 3) intraepidermal acantholysis
on histopathological examination of skin biopsies, 4)
intraepidermal IgG and/or C3 deposits by direct im-
munofluorescence and presence of anti-desmoglein 1
autoantibodies, with lack of anti-desmoglein 3 autoanti-
bodies, measured by enzyme-linked immunosorbent
assay (ELISA) method. Patients diagnosed with other
subtypes than PV or PF were not included in our study.
The collected epidemiological variables were the
age of onset, gender, ethnicity, alcohol consumptionand smoking status. The clinical variables were the
subtype of disease (PV/PF), subtype of pemphigus
vulgaris (cutaneous, mucosal, mucocutaneous), asso-
ciated comorbidities at diagnosis, value of erythrocyte
sedimentation rate (ESR) (mm/h) at diagnosis, initial
dose of corticosteroids (mg/kg/day) and follow-up time.
The immunopathological features recorded were the
direct immunofluorescence microscopy (DIF) findings,
titres of anti-desmoglein1 (Dsg1) and anti-desmoglein3
(Dsg3) autoantibodies.Collection of immunopathological data
DIF was performed in all patients. In order to deter-
mine levels of specific anti-Dsg1 and anti-Dsg3 auto-
antibodies at diagnosis, commercially available ELISA
kits were used (MBL laboratories, Nagoya, Japan). The
cut-off value for positive levels of anti-desmoglein1 and
anti-desmoglein3 autoantibodies was taken as ≥ 20 U/mL.
To use standardized conditions, reduce bias and
pre-analytical sources of error, sera from newly diag-
nosed patients were frozen after collection. Subse-
quently, ELISA analyses were performed at regular
intervals.Endpoints
The overall survival (OS) rate, representing the period
(months) from diagnosis to death, was chosen as end-
point. Overall survival was assessed after a follow-up of
minimum 12 months.
For the survival analysis, the cut off values used for
numeric continuous variables were similar to those
found in the literature. Age was assessed both as a
continuous and dichotomous variable. Since informa-
tion on age as a risk factor for overall mortality in
pemphigus is largely lacking, in line with the World
Health Organisation definition of an “elderly” or
“older” person [16] we used the cut-off value of
65 years. A level of ESR > 30 mm/h has been previously
described as risk factor for death among patients with
bullous pemphigoid [17]. Therefore, we have chosen it
as cut-off value.
A previous categorization of levels of anti-desmoglein
autoantibodies has been made by Saha et al. [8], who
divided the values in three groups, as follows: 0–29
(negative), 30–100 (low and medium levels), >100 (high
levels). For the levels of anti-desmoglein 1 and anti-
desmoglein 3 autoantibodies, we have taken as cut-off
value the level of 100 U/ml, in order to check if there
was a survival difference between patients with high
levels and patients with negative, low and medium
levels, as previously described.
The cut-off value for the corticosteroid dose was
1 mg/kg/day.
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Association between potential risk factors (epidemio-
logical, clinical and immunopathological variables de-
fined above) was assessed using the log-rank test and the
Kaplan Meier curves. The hazard ratios (HR) were com-
puted for all potential risk factors after adjusting for the
effect of age as a continuous and dichotomous variable
using a Cox proportional hazard model. Subsequently, a
multivariate Cox regression analysis was performed,
using Akaike information criterion for stepwise back-
ward/forward model selection. Hazard ratios are
presented with 95% confidence intervals. The Mann
Whitney U test, medians and interquartile range were
used for non‐normally distributed variables. For all
tests, a two-tailed p-value < 0.05 was considered statisti-
cally significant. Statistical analysis was performed using
the R software environment for statistical computing
and graphics [18].
Results
Out of the 130 patients enrolled in the study, 108
(83.1%) were diagnosed with PV and 22 (16.9%) with
PF. The HRs adjusted for age of onset as continuous
variable are shown in Table 1 for PV patients and
Table 2 for PF patients. Survival differences between
groups at 1, 3, 5 and 10 years are shown in Table 3 for
patients with PV and Table 4 for patients with PF. Only
relevant Kaplan Meier curves have been shown (Figures 1,
2, 3 and 4).
Outcome data
Among patients with PV, a total of 17 died (11 females,
6 males), 9 of them within the first year after diagnosis.
The median overall survival among the patients who
died was 8 months [2–68]. The median duration of
follow up among the patients who were alive was
58 months [2–192]. Among patients with PF, 5 died, 2
of them within the first year after diagnosis. All of
them were females. The median overall survival among
the patients who died was 17 months [5-36]. The
median duration of follow up among the patients who
were alive was 68 months [6–126]. In the pemphigus
vulgaris group, the cause of death was retrievable in 7
patients, out of which 4 showed an “early death”,
within the first year after diagnosis. A number of 5
patients died of “pemphigus-related” causes, out of
which 3 within the first year. One patient refused to
pursue the medication and died of malnutrition,
6 months after diagnosis. One patient developed an
extended form of pemphigus and died of MRSA sepsis,
7 months after diagnosis. Three patients developed an
aggressive relapse and died due to the complications
induced by corticosteroid therapy (one with gastro-
intestinal bleeding, one with pulmonary embolism andone with cardiac insufficiency), one at 2 months after
diagnosis (gastrointestinal bleeding). Two patients
died of ''non-pemphigus related'' causes (one of acute
myocardial infarction, 3 months after diagnosis and
one of stroke).
In the pemphigus foliaceus group, the cause of death
was available in 2 patients. One patient died of ''pem-
phigus-related causes'', within one year after diagnosis.
She developed a relapse and refused to continue the
treatment. Additionally, she had a type 2 diabetes melli-
tus and renal-failure. One patient died of ''non-pem-
phigus related'' cause (i.e., colorectal carcinoma) 3 years
after diagnosis.
The median interval from onset to diagnosis in the
pemphigus vulgaris group was 3 months, ranging be-
tween 0 and 48 months. The median interval from onset
to diagnosis in the pemphigus foliaceus group was
5 months, ranging between 1 and 36 months.
The interval between onset and diagnosis in the PV
group of patients who died within the first year after
diagnosis varied between 0 and 7 months. Seven of these
patients had an age > 65 years and 2 patients had an age
< 65 years. In the pemphigus foliaceus group, two
patients died within the first year after diagnosis. Both
had an age > 65 years. They were diagnosed 1, respect-
ively 2 months after the onset.
Influence of epidemiological characteristics on the overall
survival rate
An age of onset ≥ 65 years is associated with a higher risk
of overall mortality in patients with pemphigus vulgaris
and foliaceus
The median age of onset was 50 years [15–83] in the PV
group and 53 [26–87] in the PF group. PV patients with
an age of onset ≥ 65 years showed a higher risk for
overall mortality, compared to patients with an age of
onset < 65 years (HR = 9.37 (95% CI, 3.3-26.65), p <
0.001). Age of onset taken as a continuous variable
also represented a risk factor for overall mortality
(HR age = 1.12 (95% CI, 1.06 – 1.18), p < 0.001). PV
patients with an age of onset ≥ 65 years also demon-
strated a lower OS rate at 1, 3, 5 and 10 years (p <
0.001). PF patients with an age of onset ≥ 65 years
showed a higher risk for overall mortality, compared
to patients with an age of onset < 65 years (HR =
13.48 (95% CI, 1.49 –121.94), p = 0.021). In this sub-
group, age taken as a continuous variable also repre-
sented a risk factor for overall mortality (HR age =
1.09 (95% CI,1.01 – 1.16), p = 0.025). These patients
also demonstrated a lower OS rate at 3, 5 and
10 years (p = 0.003).
Female to male ratio was 1.34:1 among patients with
PV and 3:1 among those with PF. The main ethnicity in
our studied population was Romanian (92.6% of patients
Table 1 Age of onset in years, adjusted HR analysis for overall survival rates in patients with pemphigus vulgaris
Characteristic No (%) Deaths HR (95% CI) p-value
No (%)
Age of onset ≥ 65 years 27 (25.0%) 12 (70.6%) 9.37 (95%CI 3.3 – 26.65) <0.001
Age of onset < 65 years 81 (75.0%) 5 (29.4%)
Gender (M) 46 (42.6%) 6 (35.3%) 0.73 (0.26 – 2.09) 0.561
Gender (F) 62 (57.4%) 11 (64.7%)
Ethnicity (Romanian) 100 (92.6%) 16 (94.1%) 0.57 (0.07 – 4.12) 0.588
Ethnicity (Roma) 8 (7.4%) 1 (5.9%)
Alcohol consumption (Yes) 20 (18.5%) 3 (17.7%) 1.52 (0.42 – 5.51) 0.524
Alcohol consumption (No) 88 (81.5%) 14 (82.3%)
Smoking (Yes) 29 (26.9%) 2 (11.8%) 1.36 (0.29 – 6.33) 0.698
Smoking (No) 79 (73.1%) 15 (88.2%)
Subtype of PV
Mucocutaneous 80 (74.1%) 14 (82.3%) 2.60 (0.34 – 19.93) 0.357
Cutaneous 13 (12.0%) 1 (5.9%)
Mucous 15 (13.9%) 2 (11.8%) 1.72 (0.16 – 18.97) 0.659
High blood pressure (Yes) 28 (25.9%) 6 (35.3%) 0.95 (0.35 – 2.60) 0.928
High blood pressure (No) 80 (74.1%) 11 (64.7%)
Coronary heart disease (Yes) 11 (10.2%) 5 (29.4%) 3.04 (1.07 – 8.67) 0.037
Coronary heart disease (No) 97 (89.8%) 12 (70.6%)
Heart failure (Yes) 4 (3.7%) 1 (5.9%) 0.63 (0.08 – 4.76) 0.651
Heart failure (No) 104 (96.3%) 16 (94.1%)
Cardiac arrhythmia (Yes) 5 (4.6%) 3 (17.7%) 2.70 (0.75 – 9.59) 0.125
Cardiac arrhythmia (No) 103 (95.4%) 14 (82.3%)
Diabetes mellitus (Yes) 8 (7.4%) 2 (11.8%) 0.91 (0.21 – 3.99) 0.898
Diabetes mellitus (No) 100 (92.6%) 15 (88.2%)
Stroke (Yes) 5 (4.6%) 1 (5.9%) 1.08 (0.14 – 8.22) 0.944
Stroke (No) 103 (95.4%) 16 (94.1%)
Depression (Yes) 5 (4.6%) 1 (5.9%) 2.09 (0.27 – 16.22) 0.480
Depression (No) 103 (95.4%) 16 (94.1%)
Dental problems (Yes) 57 (52.8%) 7 (41.2%) 0.85 (0.32 – 2.28) 0.750
Dental problems (No) 51 (47.2%) 10 (58.8%)
ESR ≥ 30 mm/hour 26 (42.6%) 9 (75.0%) 1.51 (0.37 – 6.20) 0.570
ESR < 30 mm/hour 35 (57.4%) 3 (25.0%)
Steroids ≥ 1 mg/kg/day 15 (15.0%) 2 (14.3%) 0.88 (0.19 – 4.05) 0.868
Steroids < 1 mg/kg/day 85 (85.0%) 12 (85.7%)
Anti-Dsg1 autoAbs ≥ 100 U/mL 45 (45.5%) 11 (64.7%) 1.98 (0.71 – 5.53) 0.195
Anti-Dsg1 autoAbs < 100 U/mL 54 (54.5%) 6 (35.3%)
Anti-Dsg3 autoAbs ≥ 100 U/mL 71 (71.7%) 11 (64.7%) 0.60 (0.22 – 1.63) 0.314
Anti-Dsg3 autoAbs <100 U/mL 28 (28.3%) 6 (35.3%)
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ethnicity was Roma (7.4% of patients with PV). Gender
and ethnicity were not found to be related to overall
mortality and did not influence the OS in the PV and PF
groups (p > 0.05).We could not find alcohol intake and smoking status
as statistically significant risk factors for overall mortality
in patients with PV and PF (p > 0.05). Still, smokers with
both PV and PF had a higher OS rate, compared to non-
smokers (p > 0.05).
Table 2 Age of onset in years, adjusted HR analysis for overall survival rates in patients with pemphigus foliaceus
Characteristic No (%) Deaths HR (95% CI) p-value
No (%)
Age of onset ≥65 years 7 (31.8%) 4 (80.0%) 13.48 (1.49 – 121.94) 0.021
Age of onset <65 years 15 (68.2%) 1 (20.0%)
Gender (M) 4 (18.2%) 0 (0.0%) NA NA
Gender (F) 18 (81.8%) 5 (100.0%)
Alcohol (Yes) 2 (9.1%) 0 (0.0%) NA NA
Alcohol (No) 20 (90.9%) 5 (100.0%)
Smoking (Yes) 9 (40.9%) 0 (0.0%) NA NA
Smoking (No) 13 (59.1%) 5 (100.0%)
High blood pressure (Yes) 6 (27.3%) 2 (40.0%) 0.58 (0.09 – 3.80) 0.570
High blood pressure (No) 16 (72.7%) 3 (60.0%)
Coronary heart disease (Yes) 3 (13.6%) 1 (20.0%) 3.07 (0.26 – 36.36) 0.375
Coronary heart disease (No) 19 (86.4%) 4 (80.0%)
Diabetes mellitus (Yes) 2 (9.1%) 1 (20.0%) 7.79 (0.54 – 111.18) 0.130
Diabetes mellitus (No) 20 (90.9%) 4 (80.0%)
Dental problems (Yes) 12 (54.5%) 2 (40.0%) 1.77 (0.24 – 13.24) 0.579
Dental problems (No) 10 (45.5%) 3 (60.0%)
ESR ≥ 30 mm/hour 7 (31.8%) 2 (40.0%) NA NA
ESR < 30 mm/hour 5 (22.7%) 0 (0.0%)
Steroids ≥ 1mg/kg/day 4 (18.2%) 1 (20.0%) NA NA
Steroids < 1 mg/kg/day 12 (54.5%) 2 (40.0%)
Anti-Dsg1 autoAbs ≥ 100 U/mL 12 (54.5%) 4 (80.0%) 2.59 (0.28 – 24.13) 0.404
Anti-Dsg1 autoAbs < 100 U/mL 10 (45.5%) 1 (20.0%)
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Presence of coronary heart disease and cardiac arrhythmia
at diagnosis is associated with a higher risk of overall
mortality in patients with pemphigus vulgaris
Subtype of pemphigus (PV vs. PF) was not found to be
related to overall mortality (p = 0.701). Although patients
with PV showed a slightly higher OS survival rate at 1, 3,
5 and 10 years, compared to patients with PF, the results
were not statistically significant (p = 0.559).
Of the 108 patients with PV, 80 (74.1%) presented mu-
cocutaneous involvement, 13 (12.0%) presented only cu-
taneous involvement, while 15 (13.9%) presented only
mucous involvement. The subtype of PV (mucocuta-
neos, cutaneous, mucous) was not found to be related to
overall mortality (p > 0.05). Patients with mucocutaneous
subtype showed lower OS rates, at 1, 3, 5 and 10 years
compared to patients with cutaneous and mucous sub-
type (p > 0.05).
The evaluated comorbidity profile in patients with
PV consisted of the following nosological entities: high
blood pressure, coronary heart disease, heart failure,
cardiac arrhythmia, diabetes mellitus, stroke, depression
and dental problems. None of the patients with PFassociated heart failure, cardiac arrhythmia, stroke and
depression as comorbidities. Thus, these variables have
not been assessed as risk factors in patients with PF.
Presence of these comorbidities was assessed at diagno-
sis, in a cross-sectional manner (presence or absence of
the comorbidity at diagnosis). Patients have been diag-
nosed with coronary heart disease by a cardiologist or
general practitioner, before the diagnosis of pemphigus
has been made. Coronary heart disease was defined ac-
cording to the criteria included in the guidelines of the
European Society of Cardiology [19].
In the PV group, association of coronary heart disease
(HR = 4.27 (95% CI, 1.5- 12.13), p = 0.006) and cardiac
arrhythmia (HR = 6.19 (95% CI, 1.77-21.64), p = 0.004) at
diagnosis represented statistically significant risk factors
for overall mortality in the initial univariate analysis.
Adjusting by age, revealed coronary heart disease as a
statistically significant risk factor for overall mortality
(HR = 3.04 (95% CI, 1.07 – 8.67), p = 0.037 for age
adjusted as continuous variable and HR = 2.96 (95%
CI,1.03 – 8.54), p = 0.044 for age adjusted as dichotom-
ous variable), while cardiac arrhythmia did not represent
a statistically significant risk factor for overall mortality
(HR = 2.70 (0.75 – 9.59), p = 0.125, for age adjusted as
Table 3 Differences between survival rates at 1, 3, 5 and 10 years, in patients with pemphigus vulgaris
Characteristic Survival rate (%) 3 5 10 p-value
Follow up (years) 1
Age of onset ≥ 65 years 72.2% 67.4% 48.4% 41.5% < 0.001
Age of onset < 65 years 97.3% 97.3% 91.4% 91.4%
Survival difference (%) 25.1% 29.9% 43.0% 49.9%
Gender (M) 88.0% 88.0% 83.6% 83.6% 0.611
Gender (F) 93.3% 91.3% 78.7% 75.1%
Survival difference (%) 5.3% 3.3% 4.9% 8.5%
Ethnicity (Romanian) 90.6% 89.3% 81.1% 79.0% 0.816
Ethnicity (Roma) 100.0% 100.0% 75.0% 75.0%
Survival difference (%) 9.4% 10.7% 6.1% 4.0%
Alcohol consumption (Yes) 83.3% 83.3% 83.3% 83.3% 0.997
Alcohol consumption (No) 92.8% 91.4% 80.1% 77.5%
Survival difference (%) 9.5% 8.1% 3.2% 5.8%
Smoking (Yes) 92.1% 92.1% 92.1% 92.1% 0.299
Smoking (No) 90.9% 89.4% 78.1% 75.6%
Survival difference (%) 1.2% 2.7% 14.0% 16.5%
Subtype of PV
Mucocutaneous 90.8% 89.2% 76.8% 76.8% 0.692
Cutaneous 92.3% 92.3% 92.3% 92.3%
Mucous 92.9% 92.9% 92.9% 79.6%
High blood pressure (Yes) 88.5% 83.6% 77.2 % 70.7 % 0.303
High blood pressure (No) 92.0% 92.0% 81.8% 81.8%
Survival difference (%) 3.5% 8.4% 4.6% 11.1%
Coronary heart disease (Yes) 70.7% 70.7% 58.9% 44.2% 0.003
Coronary heart disease (No) 93.4% 92.0% 83.1% 83.1%
Survival difference (%) 22.7% 21.3% 24.2% 38.9%
Heart failure (Yes) NA 100.0% 100.0% 0.0% 0.697
Heart failure (No) 90.8% 89.5% 79.9% 79.9%
Survival difference (%) NA 10.5% 20.1% 79.9%
Cardiac arrhythmia (Yes) 53.3% 53.3% 53.3% 26.7% 0.001
Cardiac arrhythmia (No) 92.8% 91.5% 81.7% 81.7%
Survival difference (%) 39.5% 38.2% 28.4% 55.0%
Diabetes mellitus (Yes) 87.5% 87.5% 65.6% 65.6%
Diabetes mellitus (No) 91.5% 90.2% 81.8% 79.6%
Survival difference (%) 4.0% 2.7% 16.2% 14.0% 0.438
Stroke (Yes) 80.0% 80.0% 80.0% 80.0% 0.749
Stroke (No) 91.7% 90.5% 80.6% 78.4%
Survival difference (%) 11.7% 10.5% 0.6% 1.6%
Depression (Yes) 80.0% 80.0% 80.0 % 80.0% 0.629
Depression (No) 91.7% 90.4% 80.8% 78.7%
Survival difference (%) 11.7% 10.4% 0.8% 1.3%
Dental problems (Yes) 90.5% 88.0% 84.8% 84.8% 0.508
Dental problems (No) 91.9% 91.9% 77.2% 73.6%
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Table 4 Differences between survival rates at 1, 3, 5 and 10 years, in patients with pemphigus foliaceus
Characteristic Survival rate (%)
Follow up (years)1
3 5 10 p-value
Age of onset ≥ 65 years 68.6% 34.3% 34.3% 34.3% 0.003
Age of onset < 65 years NA 93.3% 93.3% 93.3%
Survival difference (%) NA 59.0% 59.0% 59.0%
Gender (M) NA NA 100.0% 100.0% NA
Gender (F) 88.5% 70.8% 70.8% 70.8%
Survival difference (%) NA NA 29.2% 29.2%
Alcohol (Yes) NA NA NA 100.0% NA
Alcohol (No) 89.7% 73.9% 73.9% 73.9%
Survival difference (%) NA NA NA 26.1%
Smoking (Yes) NA 100.0% 100.0% 100.0% NA
Smoking (No) 83.9% 58.7% 58.7% 58.7%
Survival difference (%) NA 41.3% 41.3% 41.3%
High blood pressure (Yes) 83.3% 66.7% 66.7% 66.7% 0.518
High blood pressure (No) 93.3% 80.0% 80.0% 80.0%
Survival difference (%) 10.0% 13.3% 13.3% 13.3%
Coronary heart disease (Yes) 66.7% 66.7% 66.7% 66.7% 0.545
Coronary heart disease (No) 94.4% 77.8% 77.8% 77.8%
Survival difference (%) 27.7% 11.1% 11.1% 11.1%
Diabetes mellitus (Yes) 50.0% 50.0% 50.0 % 50.0% 0.197
Diabetes mellitus (No) 94.7% 79.0% 79.0% 79.0%
Survival difference (%) 44.7% 29.0% 29.0% 29.0%
Dental problems (Yes) 82.5% 82.5% 82.5% 82.5% 0.623
Dental problems (No) NA 70.0% 70.0% 70.0%
Survival difference (%) NA 12.5% 12.5% 12.5%
Table 3 Differences between survival rates at 1, 3, 5 and 10 years, in patients with pemphigus vulgaris (Continued)
Survival difference (%) 1.4% 3.9% 7.6% 11.2%
ESR ≥ 30 mm/hour 84.6% 80.4% 66.4% 60.9% 0.039
ESR < 30 mm/hour 93.6% 93.6% 88.9% 88.9%
Survival difference (%) 9.0% 13.2% 22.5% 28.0%
Steroids ≥ 1 mg/kg/day 93.3% 93.3% 84.9% 84.8% 0.726
Steroids < 1 mg/kg/day 93.6% 92.0% 81.0% 78.1%
Survival difference (%) 0.3% 1.3% 3.9% 6.7%
Anti-Dsg1 autoAbs ≥ 100 U/mL 84.2 % 81.3% 68.8% 68.8% 0.039
Anti-Dsg1 autoAbs < 100 U/mL 96.1 % 96.1% 88.3% 84.9%
Survival difference (%) 11.9 % 14.8% 19.5 % 16.1%
Anti-Dsg3 auto Abs ≥ 100 U/mL 91.3% 89.5% 80.4% 80.4% 0.506
Anti-Dsg3 auto Abs < 100 U/mL 89.3% 89.3% 78.8% 71.6%
Survival difference (%) 2.0% 0.2% 1.6% 8.8%
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Table 4 Differences between survival rates at 1, 3, 5 and 10 years, in patients with pemphigus foliaceus (Continued)
ESR ≥ 30 mm/hour NA 71.4% 71.4% 71.4% NA
ESR < 30 mm/hour 100.0% 100.0% 100.0% 100.0%
Survival difference (%) NA 28.6% 28.6% 28.6%
Steroids ≥ 1 mg/kg/day NA 75.0% 75.0% 75.0% 0.695
Steroids < 1 mg/kg/day 100.0% 81.8% 81.8% 81.8%
Survival difference (%) NA 6.8% 6.8% 6.8%
Anti-Dsg1 autoAbs ≥ 100 U/mL 83.3% 66.7% 66.7% 66.7% 0.313
Anti-Dsg1 autoAbs < 100 U/mL NA 87.5% 87.5% 87.5%
Survival difference (%) 83.3% 20.8% 20.8% 20.8%
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for age adjusted as dichotomous variable). Patients who
associated these comorbidities at diagnosis have also
shown lower OS rates at 1, 3, 5 and 10 years, compared to
patients who did not associate coronary disease or cardiac
arrhythmia at diagnosis (p = 0.003 for coronary heart
disease and p = 0.001 for cardiac arrhythmia). Although
coronary disease was not found to be related to overall
mortality in patients with PF (p = 0.375), it has been
associated with a decreased OS rate at 1, 3, 5 and
10 years (p = 0.545).
High blood pressure, diabetes mellitus and dental prob-
lems were not found to be related to overall mortality in
patients with PV and PF (p > 0.05). Patients showing high
blood pressure and diabetes mellitus displayed a decreased
OS rate at 1, 3, 5 and 10 years, compared to patients with
PV or PF who did not associate these comorbidities at
diagnosis (p > 0.05).
Presence of heart failure, stroke and depression at
diagnosis were not found as additional risk factors for
overall mortality in patients with PV. A history of stroke
and depression was associated with a decreased OS rate
at 1, 3 and 5 years, in patients with PV (p > 0.05).
The median ESR value was 27 mm/h [4–104] in pem-
phigus vulgaris group and 35 mm/h [4–105] in pemphigus
foliaceus group. PV patients with an ESR ≥ 30 mm/h
showed a statistically significant decreased OS rate at 1,
3, 5 and 10 years, compared to patients with an ESR <
30 mm/h (p = 0.039). An ESR ≥ 30 mm/h did not repre-
sent a risk factor for overall mortality in patients with
PV (p > 0.05).
Regarding the administrated treatment in the PV
group, 108 patients received corticosteroids. Out of this
group, a number of 31 patients received corticosteroids
alone. 53 patients received corticosteroids in combination
with azathioprine, 9 patients received corticosteroids in
combination with cyclophosphamide, while 12 patients re-
ceived corticosteroids in combination with azathioprine
and cyclophosphamide. One patient received corticoste-
roids in combination with methotrexate. Two patientsadditionally received intravenous immunoglobulins. One
patient received dapsone alone.
Out of a total number of 22 patients with PF, 12
received corticosteroids alone, while 9 received corti-
costeroids plus azathioprine. One patient received
only topical steroids.
The mean initial dose of corticosteroids was 0.7 mg/kg/
day [0–2] in patients with PV and 0.6 mg/kg/day [0–1.5]
in patients with PF. An initial dose of corticosteroids
≥1 mg/kg was not found to be related to overall mor-
tality in patients with PV or PF (p > 0.05). Also, no dif-
ferences between survival at 1, 3, 5 and 10 years have
been observed between patients with an initial dose of
steroids ≥ 1 mg/kg/day and patients with an initial dose
of steroids < 1 mg/kg/day (p > 0.05).
Influence of immunopathological characteristics on the
overall survival rate
A level of anti-desmoglein 1 autoantibodies ≥100 U/mL at
diagnosis associates with a higher risk of overall mortality
in patients with pemphigus vulgaris
Values of anti-Dsg1 and anti-Dsg3 autoantibodies were
measured in 99 patients with PV and 22 patients with
PF. In the PV group, anti-Dsg1 autoantibodies were
positive in 57 patients (71.2%) with mucocutaneous type,
8 patients (61.5%) with cutaneous type and 3 patients
(20.0%) with mucous type. Anti-Dsg3 autoantibodies
were positive in 68 patients (85.0%) with mucocutaneous
type, 10 patients (76.9%) with cutaneous type and 13
patients (86.7%) with mucous type.
The median value of anti-Dsg1 autoantibodies was 80
U/mL [0–1000] in PV patients and 182 U/mL [1–12381]
in PF patients. The median value of anti-Dsg3 autoanti-
bodies was 175 U/mL [0–8121] in patients with PV.
A level of anti-Dsg1 autoantibodies ≥ 100 U/mL at
diagnosis was significantly associated with an increased
risk for overall mortality among patients with PV (HR =
2.76 (95% CI, 1.01–7.5), p = 0.047), but not PF (p > 0.05),
in the initial univariate analysis. When adjusted by age,
the serum levels of anti-Dsg1 autoantibodies did not
Figure 1 Kaplan-Meier analysis of survival in PV patients with an age of onset ≥ 65 years vs. patients with an age of onset <65 years.
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mortality (HR = 1.98 (95% CI, 0.71 – 5.53), p = 0.195, for
age adjusted as continuous variable and HR = 2.37 (95%
CI, 0.87 – 6.46), p = 0.093, for age adjusted as dichotom-
ous variable). Also, patients with PV and a level of anti-
Dsg1 autoantibodies ≥ 100 U/mL showed a lower OS
rate at 1, 3, 5 and 10 years, compared with patients with
a level of anti-Dsg1 autoantibodies <100 U/mL (p =
0.039). Patients with PF and a level of anti-Dsg1 auto-
antibodies ≥ 100 U/mL have also shown a lower OS rateFigure 2 Kaplan-Meier analysis of survival in PV patients with coronary hea
diagnosis, stratified by age.at 3, 5 and 10 years, compared with patients with a level
of anti-Dsg1 autoantibodies < 100 (p > 0.05). In patients
with PV we didn't find statistically significant differences
with respect to levels of anti-Dsg1 autoantibodies, when
the groups were divided by age, coronary heart disease
and cardiac arrhythmia. The median and interquartile
range for anti-Dsg1 autoantibodies were: age at onset ≥
65 years 104 (5.33 - 160.6) U/mL versus < 65 years 62.05
(12.65 - 187.25) U/mL, p = 0.972; coronary heart disease
present 53.8 (7.7 - 128) versus absent 81 (13.3 - 189), prt disease (CHD) vs. patients without coronary heart disease (CHD) at
Figure 3 Kaplan-Meier analysis of survival in PV patients with cardiac arrhythmia vs. patients without cardiac arrhythmia at diagnosis, stratified by age.
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versus absent 80.25 (13.95 - 188.5), p = 0.444.
An initial serum level of anti-Dsg3 autoantibodies ≥
100 U/mL could not be identified as risk factor for
overall mortality among patients with PV (p = 0.314).
We have not observed statistically significant differ-
ences between OS rates of patients with anti-Dsg3
autoantibodies ≥ 100 U/mL and anti-Dsg3 autoanti-
bodies < 100 U/mL (p = 0.506).
For the multivariate analysis we started with a model
that used all the variables assessed in the univariateFigure 4 Kaplan-Meier analysis of survival in PV patients with level of anti-
autoantibodies <100 U/mL at diagnosis, stratified by age.analysis, excluding some due either to collinearity issues
(i.e., cardiac arrhythmia) or to limited data availability in
all patients (e.g., erythrocyte sedimentation rate and dose
of steroids), and then we used a stepwise selection pro-
cedure to identify important predictors.
For the multivariate analysis, age was assessed both as
a continuous and dichotomous variable. The identified
independent risk factors for overall mortality in patients
with PV using age as a continuous variable were: age of
onset (years) (adjusted HR = 1.12 [1.06 - 1.19], p < 0.001)
and presence of coronary heart disease at diagnosisDsg1 autoantibodies ≥ 100 U/mL vs. patients with level of anti-Dsg1
Baican et al. Orphanet Journal of Rare Diseases  (2015) 10:48 Page 11 of 14(adjusted HR = 3.04 [1.07 - 8.67], p = 0.037). To further
explore the relevance of autoantibody levels as risk
factor, we manually entered in the previous model the
“autoantibody” variable and found the HRs for: anti-
Dsg1 autoantibodies ≥ 100 U/mL 2.73 [0.92 – 8.13],
p = 0.072; age of onset (years) 1.11 [1.05 – 1.17], p <
0.001; and presence of coronary heart disease at diag-
nosis 4.21 [1.38 – 12.83], p = 0.011.
The identified independent risk factors for overall
mortality among patients with PV using age as a dichot-
omous variable were: age of onset ≥ 65 years) (adjusted
HR = 7.82 [2.71 – 22.59], p < 0.001) and presence of cor-
onary heart disease at diagnosis (adjusted HR = 2.97
[1.03 – 8.58], p = 0.044). Likewise we further explored by
manually entering in the model the anti-Dsg1 autoanti-
bodies ≥ 100 U/mL, and found the HR for: anti-Dsg1
autoantibodies ≥ 100 U/mL 3.26 [1.13 – 9.40], p = 0.029;
age of onset ≥ 65 years HR = 7.49 [2.61 – 21.54], p <
0.001, and presence of coronary heart disease at diagno-
sis (adjusted HR = 4.23 [1.40 – 12.84], p = 0.011). In pa-
tients with PF, a model containing only the variable age
was selected by the stepwise procedure.
Discussion
An age of onset ≥ 65 years, presence of coronary heart
disease, cardiac arrhythmia and a level of anti-Dsg1
autoantibodies ≥ 100 U/mL at diagnosis were found to
be related to overall mortality in patients with PV. An
age of onset ≥ 65 years was found to be related to overall
mortality among patients with PF.
A considerable proportion of “early” deaths within the
first year after diagnosis has been observed in our group
(9 out of 17 patients with PV and 2 out of 5 patients
with PF). Based on the causes and age of death in this
group of patients described in the Results section and
also based on the fact that the diagnosis has been made
relatively early after onset, as mentioned above, we could
speculate that the important percentage of ''early deaths''
has been due rather to an older age of onset and to
pemphigus-related complications, than to a delayed initi-
ation of treatment.
The results of the present study confirmed that gen-
eral prognostic factors for survival, including older age
of onset and cardiovascular disease, are associated with
death also in patients with pemphigus. In line with our
data, previous studies suggested that an increased age of
onset (ranging 60–75 years) represents a risk factor for
survival in patients with PV [3,10,11,13].
Regarding the cardiovascular disease, a higher risk
of death by this cause in pemphigus population, com-
pared to general population has been previously re-
ported by Huang et al. [3]. Still, the overall survival in
pemphigus patients with cardiovascular comorbidities,
versus pemphigus patients without cardiovascularcomorbidities has not yet been addressed. In addition to
the direct cause of death, there are a few possible explana-
tions for the association of cardiac diseases with an in-
creased risk of overall mortality, in patients with
pemphigus.
Presence of a chronic inflammatory background may
represent a link between pemphigus, cardiovascular
comorbidities and a lower overall survival, due to the
direct involvement of various cytokines, such as TNF
alpha and IL-6. Both molecules have been shown to be
involved in the pathogenesis of pemphigus [20,21], as
well as atherosclerosis and coronary heart disease [22].
Although we live in the era of TNF-alpha inhibitors, the
role of these agents in pemphigus therapy is still contro-
versial, as only a limited efficacy has been proved
[23-26]. Therefore, while TNF-alpha inhibitors were
shown to reduce development of cardiovascular disease
in patients with psoriasis [27], no evidence regarding
such an effect is available in pemphigus.
Additionally, an increased inflammatory status in pem-
phigus could lead to an increased disease activity and,
consequently, to a poor outcome. In our cohort, pres-
ence of an inflammatory background in PV patients,
illustrated by an ESR ≥ 30 mm/h, was shown to be
associated with a statistically significant lower overall
survival at 1,3,5 and 10 years, compared to patients with
an ESR < 30 mm/h (p = 0.039). Rzany et al. demon-
strated similar findings among patients with bullous
pemphigoid [17]. Still, this association has not been pre-
viously reported in patients with pemphigus and could,
in our opinion, be explained by the two theories men-
tioned above, regarding the presence of a subsequently
increased disease activity or an increased cardiovascular
risk, due to the chronic inflammatory background.
An alternatively, but not most likely explanation would
be the cross-reactivity hypothesis. Desmosomes are cell
adhesion molecules, known to maintain the integrity of
various organs subjected to mechanical stress, such as
the skin or the heart [28]. It has been shown that
patients from El –Bagre, Colombia, affected by a new vari-
ant of endemic pemphigus foliaceus, displayed autoanti-
bodies against multiple cardiac epitopes [29]. Additionally,
patients with pemphigus and atypical variants of myocar-
dial infarction developed a high titre of anti-heart autoanti-
bodies, that diminished after corticotherapy [30].
As a paradox, smoking, a very-well known risk factor
for cardiovascular comorbidities, was proved to show a
limited beneficial effect in pemphigus outcome, due to
nicotine, an agonist for the acethylcoline receptors,
which are known to play an important role in the patho-
genesis of pemphigus [31,32]. In our study, smokers with
PV and PF demonstrated a higher OS rate at 1, 3, 5 and
10 years, compared with non-smokers, albeit not reach-
ing statistical significance (p > 0.05).
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diagnosis''. Our data related to smoking should be inter-
preted cautiously, because our knowledge on the effects
of smoking on the disease severity of pemphigus is lim-
ited and is based on few observational retrospective
studies and case reports [31,33-37]. Therefore, a causal
link between smoking and a clinical improvement in
pemphigus cannot be established. Based on the current
hypotheses, the actual current smoking exposure, rather
than the cumulative long-term nicotine dose, is likely
relevant for the pemphigus disease activity. Moreover,
patients with severe forms of pemphigus tend to cease
smoking, in order to improve their survival. In addition,
a dose-dependent effect of nicotine on the disease sever-
ity in pemphigus has largely not yet been addressed
thorough enough. Therefore, in an initial approach we
did not go beyond correlating the smoker/non-smoker
status with the survival. Nevertheless, smoking cannot
be suggested as therapy in patients with pemphigus. Fu-
ture studies addressing this issue in-depth in patients
and animal models of pemphigus should clarify the role
of nicotine in pemphigus and provide a basis for devel-
oping therapies using alternative cholinergic agents or
similar derivates.
A remarcable finding of the present study is related to
the prognostic relevance of the level of pemphigus auto-
antibodies at the time of diagnosis. Patients with PV and
a level of anti-Dsg1 autoantibodies ≥ 100 U/mL showed
a lower OS rate at 1, 3, 5 and 10 years, compared with
patients with a level of anti-Dsg1 autoantibodies < 100
U/mL (p = 0.039). Thus, a level of anti-Dsg1 autoanti-
bodies ≥100 U/mL at diagnosis represented a risk factor
for overall mortality in patients with PV (p = 0.047), in
the initial univariate analysis, but not when ajusted by
age as continuous or dichotomous variable (p > 0.05).
Patients with PF and a level of anti-Dsg1 autoantibodies
≥100 U/mL have also shown a lower OS rate at 3, 5 and
10 years, compared with patients with a level of anti-
Dsg1 autoantibodies < 100 (p > 0.05). In multivariate
analysis, level of anti-Dsg1 autoantibodies represented
an independent risk factor for overall mortality in PV
when explored by adding the anti-Dsg1 autoantibodies
≥ 100 U/mL to the initial model adjusted by age as
dichotomous (p = 0.029), but not when used as a con-
tinuous variable (p > 0.05). In patients with PV we didn't
find statistically significant differences with respect to
anti-Dsg1 autoantibodies levels when subdivided by age,
coronary heart disease and cardiac arrhythmia.
Nevertheless, our novel findings do not exclude that
autoantibody levels may represent an independent risk
factor for survival. This hypothesis should be further in-
vestigated in future studies, using larger patient groups.
While previous studies have mainly focused on asses-
sing the association between the level of autoantibodiesto desmogleins and disease activity and their predictive
value for relapse in pemphigus [7,38,39], it remains
largely unknown whether the levels of Dsg1- and Dsg3-
specific autoantibodies also represent a risk factor for
overall mortality in patients with PV. One can only
speculate that an increased titre of anti-Dsg1 autoanti-
bodies, which are present in the mucocutaneous subtype
of PV, associate with a more severe disease and, subse-
quently, reduced overall survival. Indeed, it has been
suggested that, when co-occuring with Dsg3-specific
antibodies, high levels of autoantibodies against Dsg1
associate with cutaneous involvement, which may result
in an increased risk of cutaneous infections [40], in
addition to difficulties in alimentation and subsequent
malnutrition, due to painful mucosal erosions [41].
Along the same lines, a correlation between increased
levels of anti-Dsg1 autoantibodies and a higher disease
activity has previously been reported in patients with
pemphigus [38,39]. Titres of anti-Dsg1 autoantibodies
were associated with disease severity, in the cutaneous
and especially in the mucocutaneous form of PV [38].
Regarding the association between the level of anti-Dsg3
autoantibodies and disease severity, the results are con-
troversial. While some studies have associated a higher
level of anti-Dsg3 autoantibodies with a higher disease
[7,8], a recent study found no association between levels
of anti-Dsg3 autoantibodies and disease severity in none
of the PV subtypes (mucous, cutaneous and mucocuta-
neous) [38].
In agreement with this hypothesis, patients with mu-
cous and cutaneous PV subtype respond better to ther-
apy, while patients with mucocutaneous involvement
develop more severe forms of disease [42]. In our study,
we showed that levels of anti-Dsg 1 autoantibodies pro-
vide a prognostic information. Patients with mucocuta-
neous involvement, which represented the majority of
PV cohort (74.1%), have also demonstrated a lower over-
all survival rate (p > 0.05), compared with patients with
mucous and cutaneous involvement. As described above,
the severity of the mucocutaneous type in PV is associ-
ated with an increased titre of anti-Dsg1 autoantibodies.
Our results suggest that an increased titre of anti-Dsg1
autoantibodies in patients with this PV subtype lead to
an increase in disease severity, with a higher resistance
to therapy and a lower overall survival rate.
A limitation of our study is related to a low number of
observations for several subgroup analyses, which ham-
per detecting small differences between the subgroups
(e.g., cutaneous/mucous/mucocutaneous involvement or
ethnicity).
Conclusions
In conclusion, in addition to common prognostic factors,
including older age and cardiovascular comorbidities, our
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as a candidate prediction factor for overall survival that
should be reinforced in further studies.
While this is the first detailed study of risk factors for
overall mortality among patients with pemphigus from
Romania, the findings of this study are likely to be repli-
cated in pemphigus patients from other geographic areas
or of other genetic background. The newly identified
factors have major implications for the stratification of
patients and design of personalized therapeutic plans in
the clinical setting. In addition, they should greatly facili-
tate further epidemiological studies in pemphigus.
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